LL162CT
Area: Neurología
Tipo de presentacion: Poster

In Vivo Evaluation of Dopamine Transporter in Patients with Schizophrenia, Drug-Naïve and in Antipsychotics Treatment with [99mTc]TRODAT-1 SPECT

Falascois M¹, Higuchi C², Noto C², Cordeiro Jr Q³, Furlaneto Lellis Leite M⁴, Vieira Castiglioni M L⁴, Gadelha Araripe Neto A², Affonseca Bressan R²

¹Depto de Psiquiatria - LiNC / Depto Diagnóstico por Imagem - DDI Universidade Federal de São Paulo.
²Departamento de Psiquiatria Universidade Federal de São Paulo.
³CAISM Santa Casa de Misericórdia de São Paulo.
⁴Departamento Diagnóstico por Imagem - DDI Universidade Federal de São Paulo.

Molecular imaging studies in schizophrenia have been used to evaluate the dopaminergic system, because its know that an increase dopamine release in the striatum region is associated with positive symptoms. [99mTc]TRODAT-1 is used in dopamine transporter (DAT) studies because of its role in dopamine release regulation in central nervous system. The aim of this study was to evaluate the DAT density between healthy individuals and patients with schizophrenia, drug-naïve and in antipsychotics treatment, throughout [99mTc]TRODAT-1 SPECT image analysis. One-hundred-twenty-six brain SPECT images (78 men, 48 women; aged 18-55 years), 53 diagnosed with Schizophrenia, according to DSM-IV criteria, and 73 healthy individuals were included. Image analysis was performed on Xeleris GE software by visual and semi-quantitative evaluation. Filtered Back Projection method, Butterworth filter and Chang attenuation correction were applied. Semi-quantitative evaluation was performed in transaxial slices (8 mm) making regions of interest the striatal region (STR) and using the occipital region (OCC) as non-specific DAT binding potential (DAT-BP=STR-OCC/OCC). There wasn’t significant difference for age and sex between groups. There was DAT-BP significant difference in total striatum (t=2.255 p=0.026); right striatum (t=2.286 p=0.024) and left striatum (t=4.259 p=0.000) between patients and controls. Drug-naïve (n=16) and antipsychotics treatment (n=37) patients compared to controls by ANOVA and, there was significant difference between controls and treatment patients (total striatum p=0.004, right striatum p= 0.005, left striatum p=0.000), and difference between treatment patients and drug-naïve in total striatum (p=0.024) and right striatum (p=0.041) regions after Bonferroni test. Our study showed alterations in DAT-BP values between controls and treatment schizophrenic patients and didn’t showed an increase of DAT-BP between drug-naïve and controls, but showed alterations in DAT-BP between drug-naïve and treatment patients. The results suggest that DAT is either changed in the progress of the disorder or affected by antipsychotics treatment. FAPESP-MCT/ CNPq-PRONEX no 2011/50740-5.